Pharmacokinetics and Metabolism in Drug Design: Edition 2

Dennis A. Smith · Han van de Waterbeemd · Don K. Walker

2006年8月 · 「John Wiley & Sons」から販売

この電子書籍について

In this new edition of a bestseller, all the contents have been updated and new material has been added, especially in the areas of toxicity testing and high throughput analysis. The authors, all of them employed at Pfizer in the discovery and development of new active substances, discuss the significant parameters and processes important for the absorption, distribution and retention of drug compounds in the body, plus the potential problems created by their transformation into toxic byproducts. They cover everything from the fundamental principles right up to the impact of pharmacokinetic parameters on the discovery of new drugs.
While aimed at all those dealing professionally with the development and application of pharmaceutical substances, the readily comprehensible style makes this book equally suitable for students of pharmacy and related subjects.

著者について

Dennis Smith has worked in the pharmaceutical industry for the past 30 years since gaining his Ph.D. from the University of Manchester. For the last 18 years he has been at Pfizer global research and Development, Sandwich where he is vice President-Pharmacokinetics, Dynamics and Metabolism. His research interests and publications span all aspects of Drug Discovery and Development particularly where drug metabolism knowledge can impact on the design of more efficacious and safer drugs. During this 30-year span he has helped in the Discovery and Development of eight marketed NCEs, with hopefully several more to come. He has authored over 100 publications. He is active in a teaching role holding appointments as visiting Professor at the University of Liverpool and Honorary Senior Lecturer at the University of Aberdeen and lectures widely to students at several other Universities.
His wish in much of his work is "to inspire another generation to take up the cudgel against disease".

Han van de Waterbeemd studied physical organic chemistry at the Technical University of Eindhoven and did a Ph.D. in medicinal chemistry at the University of Leiden, The Netherlands. After a post-doc with Bernard Testa at the University of Lausanne, Switzerland, he became a faculty member for 5 years and taught medicinal chemistry to pharmacy students at the universities of Berne and Basel, Switzerland. In his pharmaceutical career he worked for Roche, Pfizer and Astra-Zeneca where he is now global project leader of their platform for in silico predictions of ADME/Tax properties. He published more than 133 peer reviewed papers and book chapters, and (co-) edited 11 books. His research interests include the role of physicochemical and structural molecular properties in drug disposition and in silico modeling of ADMET properties.

Don Walker has a degree in Biochemistry from the University of London and spent four years assisting research involving the biochemistry of inborn errors of metabolism. He joined the Drug Metabolism Department at Pfizer in Sandwich in 1986 and since then has contributed to the drug metabolism and pharmacokinetic evaluations on several drug discovery and development projects including amlodopine, dofetilide, sildenafil, variconazole and maraviroc. He has published numerous papers on drug metabolism and pharmacokinetics and during his career at Pfizer he has been an active contributor to the UK Drug Metabolism Discussion Group, at various times having served as committee member, chairman and course tutor.